Introduction
Drug-resistant HIV evolves as virus replicates in the presence of the selective pressure of drug treatment [1] . Resistance to a drug diminishes the efficacy of that drug and often of members of the same drug class as well, thus diminishing the probability of identifying an effective subsequent treatment regimen [2] . By diminishing the efficacy of antiretroviral therapy, HIV drug resistance has negative implications both for treatment of individuals, for whom effective therapy has been shown to reduce morbidity and mortality, and for public health, since effective therapy can reduce transmissibility. Transmitted drug-resistant virus also impairs the response to treatment in the newly infected patient [3] .
Since the initial description of resistant virus during the phase II clinical trial of the first antiretroviral drug, zidovudine [4] , drug resistance and testing for it have become a routine part of antiretroviral drug development and clinical management, particularly of patients with virologic failure [1, 2, 5] . Although the prevalence of resistance has been reported in selected cohorts of limited size and geographic representation, the true prevalence of HIV drug resistance has not been described in any large population [6] . The objective of this study was to estimate the prevalence of antiretroviral drug resistance in a large, well-characterized study population representing adults receiving care for HIV infection throughout the contiguous United States.
Methods
The study sample is a subset of the nationally representative HIV Cost and Service Utilization Study (HCSUS) cohort, which represents the 231 000 adults under care for HIV in the contiguous United States at the start of the era of highly active antiretroviral therapy (HAART) in January and February 1996 [7] .
We located and contacted for interview 1919 patients from the HCSUS cohort, who were receiving care in urban clinics during January and February of 1996 and were alive in 1998. The patients were asked to provide an anonymous blood sample. Interviewers met the patients at the blood draw center to provide the laboratory with the patient's study ID number for matching with other study data. Interviewers also collected information about current and past antiretroviral therapies, HIV disease status, CD4 cell count and viral load history. Blood samples were shipped to Quest Diagnostics (San Juan Capistrano, California, USA), centrifuged to separate cells and plasma, which were divided into aliquots and frozen at À708C. Blood was successfully obtained, and CD4 and viral load information could be determined for 1797 patients, representing the 208 900 adults under care who survived from early 1996 to late 1998 (Fig. 1 ). This study focuses on results of drug susceptibility assays performed on 1099 blood specimens representing the 132 500 (63.4% of survivors) adults in care with > 500 HIV RNA copies/ ml plasma ('viremic' subset of the cohort population). The study procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation (institutional or regional) and with the Helsinki Declaration of 1975, as revised in 1983.
Quantitative CD4+ T-cell determinations were per- Died before blood draw (n ϭ 289) Estimated population size ϭ 22 500
Plasma HIV RNA plasma HIV RNA > 500 and drug resistance available (n ϭ 1099) Estimated population size ϭ 132 500
Plasma HIV RNA Ͻ500 and drug resistance not available (n ϭ 698) Estimated population size ϭ 76 400 Fig. 1 . The baseline HIV Cost and Service Utilization Study cohort consisted of 2864 randomly sampled members representing approximately 231 400 HIV-infected individuals who received care in early 1996 in the contiguous United States [7] . We focus on two subsamples of this cohort. The first consists of the 1797 who survived until blood specimens were drawn in 1998, and who represent approximately 208 900 'survivors'. The second consists of the 1099 who survived and had a viral load > 500 copies HIV RNA/ml plasma and who represent the 'detectable viral load' or 'viremic' subpopulation of approximately 132 500 individuals. The box representing this population on whom drug resistance assays were performed is shaded. *778 subjects are accounted for by analytic weights [10] .
by Quest Diagnostics. Aliquots of plasma were assayed for levels of HIV RNA by the Gen-Probe HIV-1 viral load assay [8] . Drug susceptibility assays were performed by the ViroLogic PhenoSense HIV assay which amplifies a gag-pol amplicon from plasma HIV RNA and inserts it into a resistance test vector [9] . We constructed analytic weights accounting for sampling and attrition to adjust the sample to represent the reference population [10] . To adjust standard errors and statistical tests for the differential weighting and complex sample design, we used the linearization method [11] implemented in the statistical package Stata [12] . For patient subgroups defined by covariates chosen a priori, such as key demographics and antiretroviral use history, we report estimated population sizes and weighted proportions. For each covariate, we present a chi-squared test of association, and a pairwise test for each subgroup versus a reference subgroup. We estimate adjusted odds ratios from a multivariate logistic regression model predicting drug resistance as a function of the covariates, and for each covariate present an F-test and a Wald pairwise t-test for each subgroup versus the reference subgroup.
Results
Drug resistance to one or more drugs was detected in virus from specimens representing an estimated 101 100 patients or 76.3% (95% CI, 73.0-79.2%) of the 132 500 surviving adults with more than 500 copies/ml HIV RNA plasma ( Table 2 , and in more detail in Table 3 .
Resistance was much more prevalent among patients who were very early adopters of HAART or who were taking nucleoside analogs at the start of the HAART era (1996) compared with patients who had not taken antiretroviral therapy up to that time. For example, 2 years later, resistance to any drug was estimated to be present in 87, 82, and 43% of these subpopulations, respectively, and resistance to all three drug classes was present in 27, 11, and 2%.
An estimated 88% of viremic survivors taking antiretroviral therapy when blood was collected had detectable resistance to one or more drugs compared with 30% of those not currently taking therapy (P ¼ 0.001).
A were demonstrated to be persistent independent predictors of resistance in a multiple logistic regression. (Table 4) .
As the cutoff criteria used to define resistance were not derived from treatment response criteria for all drugs, the study results may slightly over or under-estimate the true drug resistance prevalence, although the cutoffs utilized reflect the best current estimate of clinically significant criteria for impaired treatment responses due to drug resistance. When a much more conservative IC 50 ratio of 10 is used to define resistance for all classes of drugs, despite the fact that with several drugs significantly impaired treatment responses have been documented with lower cutoff values, the prevalence of resistance to one or more drugs among the viremic population decreased slightly to 72.6%, whereas the prevalence of resistance to non-nucleoside reverse transcriptase inhibitors decreased to 21.8% and protease inhibitors to 27.4%. These small reductions in estimated prevalence of resistance did not substantially impact the results from analyses of drug resistance risk factors.
Discussion
These first estimates of the prevalence of HIV drug resistance in adults across the United States have several clinical and public health implications, mostly deriving from the fact that suppression of circulating HIV is an important goal for improving patient outcomes and Copyright © Lippincott Williams & Wilkins. Unauthorized reproduction of this article is prohibited. reducing transmission. We found that most adult Americans who received medical care for HIV infection at urban clinics at the start of the HAART era, including essentially all urban residents and over half of the small number of rural residents receiving HIV care, survived until late 1998. However, even when considering all patients including those with early disease and those not on therapy, most survivors had viremia with . 500 copies HIV RNA/ml plasma, and most of these viremic patients had drug-resistant virus. Clinicians and policymakers need to be aware that this large population of patients with viral loads above 500 copies/ml while on therapy are likely to have more limited treatment options and a diminished probability of complete suppression of viral replication as a treatment outcome.
The drug resistance rates reported do not reflect the level of resistance among those with very low viral loads in whom resistance was not measured, and should not be generalized to that population. Even if all patients with , 500 copies HIV RNA/ml plasma were assumed to harbor no drug-resistant virus, then an estimated 48% of all 208 900 surviving adults would have drug resistance. Nevertheless we know that suppression of viremia with potent combination therapy in patients with drug-resistant virus can be attained, but the resistant virus can be archived indefinitely in the latently infected cell reservoir [13] [14] [15] . Thus the true rate in the total population regardless of plasma HIV RNA falls between the two values. The patient population characterized in this study represents a large reservoir for potential transmission of drug-resistant virus, consistent with the reports of increasing rates of transmission of drugresistant HIV in North America with resulting impaired treatment responses and heightened urgency to prevention efforts targeted at this group [3] . An additional public health concern is that patients infected with resistant virus may not come to medical attention or receive specific prevention messages for a considerable period of time. Only about one-half of the between 850 000 and 950 000 Americans infected with HIV get regular care, and that an estimated one-quarter are unaware of their infection [7, 16] .
As the data were generated from specimens taken 3 years into the era of potent combination antiretroviral therapy with protease and reverse transcriptase inhibitors, factors have been in place that could potentially impact the prevalence of drug resistance either higher or lower. The more prolonged and wider utilization of the non-nucleoside reverse transcriptase inhibitors and protease inhibitors may have increased resistance to these drug classes as well as multiple class resistance. On the other hand the diminishing practice of sequential therapy and the availability of more effective and better tolerated combination regimens, especially for patients without prolonged nucleoside treatment experience, have been shown to increase the likelihood of suppression of viremia with resulting prevention of acquired resistance [17, 18] . Active surveillance efforts will be required to monitor the trends of drug resistance among HIV-infected populations in order to assess the evolution of resistance patterns and to define optimum HIV treatment and prevention strategies. Nevertheless, these data indicate the magnitude of drug resistance that can be selected in a decade for nucleoside reverse transcriptase inhibitors in only 1 to 2 years for nonnucleoside reverse transcriptase and protease inhibitors.
Clinical approaches to address this growing drug resistance problem include the routine use of drug resistance testing to manage patients, development of new drugs active against drug-resistant virus, and the more careful and effective use of these drugs by both health care providers and patients. Because of the high rates of replication and mutation of HIV, the extensive use of antiretroviral therapy provides one of the most dramatic examples of the impact of human intervention on evolution in an ecological system [19] . HIV drug resistance frighteningly recapitulates the history of antimicrobial drug resistance in bacteria, with a pernicious twist: HIV is not curable and drug-resistant variants are archived within each patient for life. In addition, the ability of HIV to avoid inhibition by antiretroviral therapy through accumulating mutations
Copyright © Lippincott Williams & Wilkins. Unauthorized reproduction of this article is prohibited. indicates that newer and more effective therapies will continue to be needed to control the pandemic.
